Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Image-guided tumor-focused radiation therapy · 1 trial · 1 indication
Acute any attribution genitourinary or gastrointestinal toxicity (grade 2 or higher), compared between randomized arms, defined as the percentage of patients with Common Terminology Criteria for Adverse Events genitourinary or gastrointestinal toxicity of grade 2 or higher within 3 months of completing radiation therapy. Based on the Common Terminology Criteria for Adverse Event, grade 1 is the lowest and grade 5 is the highest. Grade 5 represents the worst outcome (death).
| Arm | Type | Description |
|---|---|---|
| Standard of care dose radiotherapy | NO_INTERVENTION | Standard dose radiation therapy |
| Tumor-focused radiotherapy | EXPERIMENTAL | Image-guided tumor-focused radiation therapy |
| Name | Type | Description |
|---|---|---|
| Image-guided tumor-focused radiation therapy | RADIATION | Image-guided tumor-focused radiation therapy |
Inclusion Criteria: * Provision of signed and dated informed consent form * Stated willingness to comply with all study procedures and availability for the duration of the study * At least 18 years old * Histologic confirmation of prostate adenocarcinoma with plan for curative-intent radiation ther...
Top 20 of 53 competitors
Image-guided tumor-focused radiation therapy is an investigational treatment being studied for prostate cancer. It is currently in Phase 2 clinical development, with an active trial enrolling patients with intermediate and high-risk prostate cancer. The therapy is being evaluated as a potential treatment option for this patient population.
Veracyte, Inc. (NASDAQ: VCYT) is developing Image-guided tumor-focused radiation therapy. The company is conducting a Phase 2 clinical trial of this investigational treatment for prostate cancer. The trial is actively recruiting participants in the United States.
Image-guided tumor-focused radiation therapy is in Phase 2 clinical development. It is an investigational therapy, not yet approved by regulatory authorities. A Phase 2 trial is currently recruiting patients with intermediate and high-risk prostate cancer to evaluate the treatment's efficacy and safety.
Image-guided tumor-focused radiation therapy is being studied in one active Phase 2 clinical trial, identified as NCT06990542. This trial, titled 'Image-guided, Tumor-focused Radiotherapy Treatment in Intermediate and High-risk Prostate Cancer,' is recruiting 150 male patients aged 18 years and older in the United States.
Yes, the Phase 2 clinical trial of Image-guided tumor-focused radiation therapy is randomized and controlled. The control type is no-treatment controlled, meaning some participants receive the investigational therapy while others do not receive active treatment. The trial is not double-blinded.